Antibodies News and Research

RSS

INTEGRA’s electronic pipettes eliminate user fatigue and improve pipetting productivity

CDI Labs – a biotechnology company based in Puerto Rico – is using INTEGRA’s VIAFLO and VOYAGER electronic pipettes to streamline workflows and improve accuracy for the development of next generation proteomics products.

From INTEGRA Biosciences 17 Mar 2021

New research proposes innovative antibody-based treatment to prevent SARS-CoV-2 viral entry

A brief report by researchers at the University of Virginia, USA, proposes using an antibody-based treatment with a plug-and-play strategy to inhibit the ability of SARS-CoV-2 to invade human cells.

17 Mar 2021

Compromised immunity can allow SARS-CoV-2 to evade the immune system

The vast majority of people infected with SARS-CoV-2 clear the virus, but those with compromised immunity--such as individuals receiving immune-suppressive drugs for autoimmune diseases--can become chronically infected.

17 Mar 2021

Living with a COVID-19 case brings worse symptoms and stronger antibody response

This study suggests that high virus exposure levels contribute to greater disease severity and stronger antibody responses. The observations from this study are published on the medRxiv preprint server.

17 Mar 2021

Testing for mRNA-1283, Moderna's next generation COVID-19 vaccine commences

As vaccine efforts against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease, roll out in various countries, Moderna ups the game by testing its next-generation COVID-19 vaccine.

16 Mar 2021

Salivary IgG to SARS-CoV-2 after mild COVID-19

A team of researchers based in Stockholm, Sweden, has demonstrated that individuals exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have antibodies for the disease up to nine months after acquiring the disease, even if they displayed only mild symptoms.

16 Mar 2021

New Colombian SARS-CoV-2 lineage shares antibody-resistant mutations with other variants

Scientists in Colombia have identified a new highly divergent SARS-CoV-2 lineage with Spike substitutions L249S and E484K. These same mutations have convergently appeared in other mutant strains of the virus, most notably in variants of concern.

16 Mar 2021

Saliva-based testing as a method for monitoring population immunity to SARS-CoV-2 infection

Researchers in the United States have shown that saliva-based sampling could serve as an accurate and non-invasive alternative to blood sampling for monitoring people’s antibody responses following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or vaccination against the virus.

16 Mar 2021

UTHSC professor awarded $1.79 million grant to develop new amyloidosis treatment

The National Institute of Diabetes and Digestive and Kidney Diseases recently awarded Jonathan Wall, PhD, professor in the University of Tennessee Health Science Center's Graduate School of Medicine in Knoxville, a $1.79 million grant for his study titled "Developing a Theranostic Immunotherapy for Systemic Amyloidosis."

16 Mar 2021

Study explores how SARS-CoV-2 mutations produce antibody resistance and enhanced transmissibility

An interesting new study deals with the effects of the natural mutations in the spike antigen of the SARS-CoV-2, the pathogen that is responsible for the ongoing coronavirus disease pandemic.

16 Mar 2021

New study tests how mutations in SARS-CoV-2 affect antibody neutralization

Using pseudoviruses with single amino acid substitutions, researchers found that mutations in SARS-CoV-2 reduce monoclonal antibody neutralization differently. However, convalescent sera samples did not lose neutralization potency many and were also effective against the B.1.1.7 (UK-derived) strain.

16 Mar 2021

New SARS-CoV-2 lineage has spread across many Brazilian states

Researchers in Brazil have identified the emergence of a new lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Brazil that has spread across multiple states in the country.

15 Mar 2021

Chimeric vaccines may provide universal protection against viruses like SARS-CoV-2

Researchers in the United States have developed “chimeric” vaccines that provided cross-protection against different strains of sarbecovirus in mice, including the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

15 Mar 2021

Scientists discover how novel pathogens promote colorectal cancer development

Do BMMFs, the novel infectious agents found in dairy products and bovine sera, play a role in the development of colorectal cancer? Scientists led by Harald zur Hausen detected the pathogens in colorectal cancer patients in close proximity to tumors.

15 Mar 2021

What is a protective neutralizing antibody titer against SARS-CoV-2 infection?

A new study describes a predictive model of protective immunity against SARS-CoV-2 infection that could help evolve optimal vaccination strategies to maintain protection and reduce the death rate.

15 Mar 2021

Why does convalescent plasma therapy for severe COVID-19 show mixed success?

A surprising new preprint, released on the medRxiv* server, suggests that the beneficial effects of convalescent plasma (CP) in this disease stem not only from the presence of neutralizing antibodies, but also the immunomodulatory effects of this plasma that shapes the host immune response.

15 Mar 2021

Neutralizing nanobodies effective against SARS-CoV-2 variants

Nanobodies have different mechanisms to neutralize viruses, and some target epitopes not accessible to monoclonal antibodies, making them an alternative for developing therapies for COVID-19.

15 Mar 2021

Research looks at inflammatory nature of lipid nanoparticle component in mRNA vaccines

In a recent bioRxiv preprint research paper, Botond Z. Igyártó and colleagues from Thomas Jefferson University demonstrated the inflammatory nature of the lipid nanoparticles (LNPs).

15 Mar 2021

Dual-action monoclonal antibodies from an original SARS survivor show promise against COVID-19

A recent study, currently available on the bioRxiv preprint server, indicates that a pair of dual-action monoclonal antibodies derived from an original 2003 SARS survivors could play an important role in the fight against coronavirus disease 2019 (COVID-19) due to their broadly neutralizing activity and the engagement of the immune system via effector function capabilities.

14 Mar 2021

Study maps crucial component of long-term immune response to SARS-CoV-2

Researchers in the United States have found that protective antibodies generated against the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)– the agent that causes coronavirus disease 2019 (COVID-19) – also protect against viral variants.

14 Mar 2021

Antibodies News and Research

INTEGRA’s electronic pipettes eliminate user fatigue and improve pipetting productivity

New research proposes innovative antibody-based treatment to prevent SARS-CoV-2 viral entry

Compromised immunity can allow SARS-CoV-2 to evade the immune system

Living with a COVID-19 case brings worse symptoms and stronger antibody response

Testing for mRNA-1283, Moderna's next generation COVID-19 vaccine commences

Salivary IgG to SARS-CoV-2 after mild COVID-19

New Colombian SARS-CoV-2 lineage shares antibody-resistant mutations with other variants

Saliva-based testing as a method for monitoring population immunity to SARS-CoV-2 infection

UTHSC professor awarded $1.79 million grant to develop new amyloidosis treatment

Study explores how SARS-CoV-2 mutations produce antibody resistance and enhanced transmissibility

New study tests how mutations in SARS-CoV-2 affect antibody neutralization

New SARS-CoV-2 lineage has spread across many Brazilian states

Chimeric vaccines may provide universal protection against viruses like SARS-CoV-2

Scientists discover how novel pathogens promote colorectal cancer development

What is a protective neutralizing antibody titer against SARS-CoV-2 infection?

Why does convalescent plasma therapy for severe COVID-19 show mixed success?

Neutralizing nanobodies effective against SARS-CoV-2 variants

Research looks at inflammatory nature of lipid nanoparticle component in mRNA vaccines

Dual-action monoclonal antibodies from an original SARS survivor show promise against COVID-19

Study maps crucial component of long-term immune response to SARS-CoV-2

Immunology eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News